State of the Art in Cystic Fibrosis Pharmacology Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations: III. Executive Summary

Pediatr Pulmonol. 2021 Mar 3. doi: 10.1002/ppul.25353. Online ahead of print.

ABSTRACT

Acute pulmonary exacerbations (APE) are complications of cystic fibrosis (CF) and are associated with increased morbidity and mortality. Methicillin-resistant Staphylococcus aureus (MRSA) and Aspergillus fumigatus are organisms that have been detected in the lungs of CF patients. The focus of this review is to provide an overview of the classes of antimicrobials used for MRSA and allergic bronchopulmonary aspergillosis (ABPA), a hypersensitivity reaction caused by Aspergillus fumigatus. The current anti-MRSA antibiotics and medications for ABPA dosing recommendations are discussed. This article also reviews the findings from the MRSA utilization surveys and the pharmacokinetic and pharmacodynamic differences between CF and non-CF patients. Anti-methicillin Staphylococcus aureus (S. aureus) antibiotics include ceftaroline, clindamycin, fluoroquinolone derivatives (ciprofloxacin, levofloxacin), glycopeptide derivatives (telavancin, vancomycin), linezolid, rifampin, sulfamethoxazole/trimethoprim, and tetracycline derivatives (doxycycline, minocycline, tigecycline). Medications used for ABPA include corticosteroids, amphotericin B, azole anti-fungals (isavuconazole, itraconazole, posaconazole, and voriconazole), and a monoclonal antibody, omalizumab. This article is protected by copyright. All rights reserved.

PMID:33656280 | DOI:10.1002/ppul.25353

Source: Industry